SR-9009 Stenabolic HPLC lab analysis certificate - sarms.co.uk

REV-ERB AGONIST · NON-SUPPRESSIVE METABOLIC COMPOUND

Stenabolic SR-9009

10mg per capsule · 90 capsules

£59.99

In stock · Order before 2pm for next-day dispatch

Purity≥99% (HPLC verified)

Active ingredient10mg per capsule

Count90 capsules

ManufacturerUK — ISO certified

Overall research score

6.8 / 10

Moderate · Metabolic research compound, oral bioavailability limitations

Metric breakdown

Metabolic activity 9.0

Endurance research 8.5

Safety profile 7.5

Bioavailability 4.0

Research depth 5.5

Suppression risk Low

Hepatotoxicity Minimal

Compound profile

Chemical name: Ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
Molecular weight: 437.94 g/mol
Half-life: ~4 hours
Detection time: Not established
Research active: 20–30mg / day
Research cycle: 4–8 weeks
CAS number: 1379686-30-2

Research applications

Metabolic research Endurance Fat oxidation Circadian rhythm research Non-suppressive

Research use only. Scores derived from published preclinical and peer-reviewed literature. Not intended for human consumption.

Description

What Is SR-9009 (Stenabolic)?

SR-9009 (Stenabolic) is an investigational compound studied in REV-ERB pathway research. This page provides a practical research reference overview with mechanism context, evidence limits, handling notes, and batch verification standards.

Compound Profile

Name	SR-9009 (Stenabolic)
CAS	1379686-30-2
Formula	C20H24ClN3O4S
Molecular Weight	437.94 g/mol
Category	Investigational REV-ERB agonist (not a SARM)
PubChem	117072549

What is sr-9009 stenabolic is a common query used by researchers differentiating circadian/metabolic pathway compounds from AR-modulating compounds.

How Does SR-9009 Work?

Published work describes SR-9009 as a REV-ERB agonist evaluated for circadian and metabolic pathway signalling in model systems. This page is technical reference content, not therapeutic guidance.

Researchers often compare sr-9009 vs sarms research when separating mechanism classes and endpoint interpretation.

What Does Current Research Say?

Preclinical literature includes metabolic, circadian, and endurance pathway discussions.
Evidence quality varies by model, duration, and endpoint type.
No broad consumer therapeutic approval exists.
Interpretation should prioritize study design and method quality.

Typical search intent includes sr-9009 dosage research use and sr-9009 cycle length research phrasing, which should be read as literature context rather than user instruction.